The invention discloses a
crystal form G of
ibrutinib. The
crystal form G is characterized in that X-
ray powder diffraction (X-RPD) which adopts Cu-Kalpha
radiation and is represented with a 2theta angle has
diffraction peaks in positions at angles of 5.0 degrees plus or minus 0.2 degrees, 7.3 degrees plus or minus 0.2 degrees, 10.1 degrees plus or minus 0.2 degrees, 12.0 degrees plus or minus 0.2 degrees, 13.2 degrees plus or minus 0.2 degrees, 17.1 degrees plus or minus 0.2 degrees, 19.5 degrees plus or minus 0.2 degrees, 20.8 degrees plus or minus 0.2 degrees, 22.3 degrees plus or minus 0.2 degrees, 24.3 degrees plus or minus 0.2 degrees, 27.4 degrees plus or minus 0.2 degrees and 31.2 degrees plus or minus 0.2 degrees. Related solvents in a preparation process of the
crystal form G are cheap, the conditions are mild, the operation is simple, good
controllability and reproducibility are realized, further, the prepared crystal form has great stability, the HPLC (
high performance liquid chromatography) purity is higher than 99%, and the phenomenon of
crystal transformation can be avoided; besides, the
solubility is high, the dissolubility is good, and the
bioavailability is high.